Douglas Flora: The importance of RWE in enhancing our understanding of treatment outcomes and patient care

Douglas Flora shared a post by Blythe Adamson, Founder, Infectious Economics, on LinkedIn adding:

“Kudos to AI in Precision Oncology editor Blythe Adamson, PhD, MPH, for her thoughtful and careful application of real-world evidence (RWE) to complement clinical trials.

RWE plays a crucial role in addressing questions that traditional trials may not fully answer, particularly when utilizing large and diverse datasets. Blythe’s work underscores the importance of RWE in enhancing our understanding of treatment outcomes and patient care. Keep pushing forward, Blythe—excited to see the innovative solutions you bring to cancer research (and your manuscripts)”

Quoting Blythe Adamson:

“This explains my motivation for spending the summer in Japan and Germany. The data is beautiful.”

Source: Douglas Flora/LinkedIn and Blythe Adamson/LinkedIn

Douglas Flora is the Executive Medical Director of Oncology Services at St. Elizabeth Healthcare, overseeing clinical operations, strategic planning, and the expansion of cancer programs. He is also the co-founder of the Center for Precision Medicine; Genomic Health.

As the Editor-in-Chief of ‘AI in Precision Oncology,’ the first peer-reviewed academic journal dedicated to this field, he plays a pivotal role in advancing research. He is also an active board member of the American Cancer Society and ACCC, where he contributes to advocacy, education, and innovation within the cancer community.